Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); LX4211 Phase 2b Trial Data Expected Soon
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Lexicon Pharmaceuticals (NASDAQ: LXRX) price target of $3.00.
Analyst, Alan Carr, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Alan Carr, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
